[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355772-105":59,"doc-detail-355772-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","reprogramming-t-cell-myeloid-crosstalk-overcomes-immune-resistance-in-colorectal-cancer","Reprogramming T cell-myeloid crosstalk overcomes immune resistance in colorectal cancer","","Colorectal cancer (CRC) accounts for 10% of cancer cases and remains a leading cause of cancer mortality. Anti-PD-1 therapy benefits many patients, yet about half of advanced mismatch repair-deficient (MMRd) and most mismatch repair-proficient (MMRp) CRC cases fail to respond. Using orthotopic and patient-derived models with single-cell and spatial profiling, the study links durable tumor control to colocalization of MHC+ C1Q+ CXCL9+ macrophages and TCF+ PRF1+ T cells. Resistance associates with elevated TIM3, LAG3, TIGIT, and PD-1 on T cells plus TREM2+ macrophages in T cell-excluded regions. Blocking TREM2, LAG3, CTLA4, and PD-1 reprograms the tumor microenvironment, achieving up to 100% clearance in MMRd and over 70% in MMRp models while promoting immune memory and reducing myeloid suppression and T cell exhaustion.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/reprogramming-t-cell-myeloid-crosstalk-overcomes-immune-resistance-in-colorectal-cancer/355772/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/reprogramming-t-cell-myeloid-crosstalk-overcomes-immune-resistance-in-colorectal-cancer/355772.png","ImageObject",300,407,{"name":92,"@type":93},"Adam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What determines response to anti-PD-1 therapy in colorectal cancer in this study?","Question",{"text":113,"@type":114},"Response associates with colocalization of MHC+ C1Q+ CXCL9+ macrophages and TCF+ PRF1+ T cells during anti-PD-1 treatment.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What immune features characterize resistance in MMRd and MMRp CRC models?",{"text":118,"@type":114},"Resistance correlates with increased TIM3, LAG3, TIGIT, and PD-1 on T cells, enrichment of TREM2+ macrophages in T cell-excluded regions, and immunosuppressive tumor microenvironment programs.",{"name":120,"@type":111,"acceptedAnswer":121},"How does the proposed combination therapy overcome immune resistance?",{"text":122,"@type":114},"A combinatorial blockade targeting TREM2, LAG3, CTLA4, and PD-1 reprograms macrophage–T cell interactions, drives antitumor immunity, promotes immune memory, and reduces myeloid-mediated suppression and T cell exhaustion, yielding up to 100% clearance in MMRd and >70% in MMRp models.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355772,1790192975,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1374404737137,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article  \nReprogramming T cell-myeloid crosstalk overcomes immune resistance in colorectal cancer  \nAuthors  \nGuillaume Mestrallet, Matthew Brown, Natalie Vaninov,   , Cansu Cimen Bozkus, Robert M. Samstein, Nina Bhardwaj  \nCorrespondence  \n[guillaume.mestrallet@mssm.edu](guillaume.mestrallet@mssm.edu) (G.M.), [robert.samstein@mountsinai.org](robert.samstein@mountsinai.org)[ ](robert.samstein@mountsinai.org)(R.M.S.),  \n[nina.bhardwaj@mssm.edu](nina.bhardwaj@mssm.edu) (N.B.)  \nIn brief  \nMestrallet et al. show that T cell-myeloid interactions determine response to PD-1 blockade in colorectal cancer. Targeting TREM2 macrophages together with LAG3, CTLA4, and PD-1 reprograms the tumor microenvironment and drives antitumor immunity, achieving up to 100% tumor clearance in mismatch repair-deficient and >70% in mismatch repair-proficient models.  \n• Resistance involves TREM2+ macrophages, multiple T cell checkpoints, and IFITM+ tumors  \n• PD-1, LAG3, CTLA-4, and TREM2 blockade prevents MMRd and MMRp tumor progression  \n• Combination therapy drives macrophage-T cell interactions and immune memory  \nMestrallet et al., 2026, Cell Reports Medicine 7, 102786  \nMay 19, 2026 © 2026 The Author(s) . Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xcrm.2026.102786](https://doi.org/10.1016/j.xcrm.2026.102786)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nReprogramming T cell-myeloid crosstalk overcomes immune resistance in colorectal cancer  \nGuillaume Mestrallet,1,* Matthew Brown,1 Natalie Vaninov,2 Nam Woo Cho,3 Leandra Velazquez,1  \nAparna Ananthanarayanan,1 Matthew Spitzer,4 Nicolas Vabret,2 Cansu Cimen Bozkus,1 Robert M. Samstein,2,5,* and Nina Bhardwaj1,5,6,*  \n1Division of Hematology and Oncology, Hess Center for Science & Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA  \n2The Marc and Jennifer Lipschultz Precision Immunology Institute, Department of Immunology and Immunotherapy, Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA  \n3Department of Radiation Oncology and the Department of Otolaryngology–Head and Neck Surgery, University of California at San Francisco, San Francisco, CA 94143, USA  \n4Department of Otolaryngology–Head and Neck Surgery and the Department of Microbiology and Immunology, University of California at San Francisco, San Francisco, CA 94143, USA  \n5These authors contributed equally  \n6Lead contact  \n*Correspondence: [guillaume.mestrallet@mssm.edu](guillaume.mestrallet@mssm.edu) (G. M.), [robert.samstein@mountsinai.org](robert.samstein@mountsinai.org) (R. M.S.), [nina.bhardwaj@mssm.edu](nina.bhardwaj@mssm.edu) (N. B.) [https://doi.org/10.1016/j.xcrm.2026.102786](https://doi.org/10.1016/j.xcrm.2026.102786)  \nSUMMARY  \nColorectal cancer (CRC) accounts for 10% of cancer cases and is the second leading cause of cancer-related deaths. Although anti-PD-1 therapy improves outcomes, 50% of advanced mismatch repair-deficient (MMRd) and most mismatch repair-proficient (MMRp) CRC cases fail to respond. Using orthotopic and patient-derived CRC models with single-cell and spatial analyses, we show that tumor control during anti-PD-1 treatment associates with colocalization of MHC+ C1Q+ CXCL9+ macrophages and TCF+ PRF1+ T cells. Resistance correlates with increased TIM3, LAG3, TIGIT, and PD-1 expression on T cells and enrichment of TREM2+ macrophages in T cell-excluded regions. A combinatorial blockade targeting TREM2, LAG3, CTLA4, and PD-1 induces up to 100% tumor clearance in MMRd and >70% in MMRp models. This strategy promotes immune memory mediated by interactions among MHC+ macrophages and CD4+/CD8+/TCF+ T cells, while reducing immunosuppressive myeloid infiltration and T cell exhaustion, identifying key cellular programs that overcome immune escape in CRC.  \nINTRODUCTION  \nUp to 30% of colorectal, endometrial, and gastric cancers exhibit deficiency in mismatch repair (MMR) protein expression due to germline or epigenetic inacti","cbCaielT0WoLCPVb","https://ap.wps.com/l/cbCaielT0WoLCPVb","pdf",12561916,23,"English","# Summary\n## Key findings and therapeutic concept\n# Introduction\n## Mismatch repair deficiency and immunogenicity\n## Limits of PD-1 checkpoint blockade and immune resistance","[{\"question\":\"What determines response to anti-PD-1 therapy in colorectal cancer in this study?\",\"answer\":\"Response associates with colocalization of MHC+ C1Q+ CXCL9+ macrophages and TCF+ PRF1+ T cells during anti-PD-1 treatment.\"},{\"question\":\"What immune features characterize resistance in MMRd and MMRp CRC models?\",\"answer\":\"Resistance correlates with increased TIM3, LAG3, TIGIT, and PD-1 on T cells, enrichment of TREM2+ macrophages in T cell-excluded regions, and immunosuppressive tumor microenvironment programs.\"},{\"question\":\"How does the proposed combination therapy overcome immune resistance?\",\"answer\":\"A combinatorial blockade targeting TREM2, LAG3, CTLA4, and PD-1 reprograms macrophage–T cell interactions, drives antitumor immunity, promotes immune memory, and reduces myeloid-mediated suppression and T cell exhaustion, yielding up to 100% clearance in MMRd and \\u003e70% in MMRp models.\"}]","Reprogramming T cell-myeloid crosstalk overcomes immune resistance in colorectal cancer | PDF",1790120878,58,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4c7fffdf70862301ed872c0b3678bb3c.webp",983,1276,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e00269b3a237a8e7ce073f45db5e73b.webp",982,1275,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ea609f928ef04a4653c62b5601349a1c.webp",981,1273,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e3c1590295ce1e9d6259b9b9ee056d1.webp",980,1272]